Trial Profile
An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Biomarker; Therapeutic Use
- 17 Nov 2021 Status changed from active, no longer recruiting to completed.
- 14 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2021 Planned End Date changed from 30 May 2022 to 30 Sep 2021.